Skip to content

Person Centered Nursing Homes: Impact Assessment Of Centered Person Care In Nursing Homes

Residències Centrades en Les Persones (RECENPE): avaluació de l'Impacte d'un Model d'ACP en residències Per Persones Grans

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03200145
Acronym
RECENPE
Enrollment
170
Registered
2017-06-27
Start date
2017-06-27
Completion date
2018-02-28
Last updated
2017-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Services for the Aged, Mood, Quality of Life

Brief summary

Cohort Observational Study. The study will assess differences in quality of life, well-being and mood between persons living in a nursing home following usual care and persons living in nursing homes following a centered person care model. Initially, the follow up will last 6 months, with the possibility to be extended.

Interventions

OTHERACP intervention

The intervention group made by persons living in nursing homes using a person centered attention model relying on two dimensions: 1. \- Attention to the person based on: * Knowledge of the person in several dimensions (biological, psychological, social, etc), interests and preferences. * Respect and acknowledge of the person. * Promotion of the autonomy. * Personalized treatment, with tailored attention and integrative cures * Protection of physical well-being, preventing damages and risks and promoting healthy habits. * Promotion of independence on daily activities. * Protection of privacy and personal matters 2. \- Positive environment based on: * Physical space, including accessibility, comfort, homely environment, with stimulating spaces for physical activity, social relationships and significant activities for the persons. * Social relationships, with proximity and collaboration with families. * Friendly organization, with empathetic professionals empowering users.

Sponsors

SUMAR empresa d'acció social de Catalunya
CollaboratorUNKNOWN
Fundacio Salut i Envelliment UAB
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Persons living in nursing homes * Consent from the person (or legal representative, if the person is not able)

Exclusion criteria

* Terminal illness * Living temporary in a nursing home

Design outcomes

Primary

MeasureTime frameDescription
Thriving in nursing homes0, 6 monthsThriving in nursing homes will be assessed with the Thriving of Older People Assessment Scale (TOPAS). Investigators will assess the change between groups.
Quality of life0, 6 monthsQuality of life will be assessed with the Euroqol 5D-5L. Investigators will assess the change between groups.
Well-being0, 6 monthsWell-being will be assessed by the WHO (Five) Well Being Index (1998 version). Investigators will assess the change between groups.

Secondary

MeasureTime frameDescription
Depressive symptoms0, 6 monthsCognitive impairment affects the assessment of depressive symptoms. For this reason, according to their stage using the Reisberg Global Deterioration Scale, investigators will assess the presence or absence of depressive symptoms with two tools * stage 0 to 4: investigators will consider that a person has depressive symptoms with a score of 6 or more using the 15 items Yesavage Geriatric Depression Scale, * stage 5 to 7: investigators will consider that a person has depressive symptoms with a score of 11 or more using the Cornell Depression Scale. Investigators will assess the change in the prevalence of depressive symptoms between groups.
Neuropsychiatric inventory0,6 monthsNeuropsychiatric symptoms will be assessed with the Brief Neuropsychiatric inventory(NPI-Q). Investigators will assess the change between groups.

Countries

Spain

Contacts

Primary ContactXavier Rojano Luque, MD
xavier.rojano@uab.cat93 433 50 53
Backup ContactAntoni Salvà Casanovas, MD
antoni.salva@uab.cat

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026